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ABSTRACT
Cancer is one of the most deadly diseases around the world. Oncolytic virus (OV) therapy
is an anti-cancer approach based on using viruses to selectively target and kill cancerous cells and
also their ability to stimulate antitumor immune responses. Vesicular stomatitis virus (VSV) has
been investigated as a great platform for an oncolytic agent. Many modifications have been made
to VSV to improve its oncolytic effects. One of such modifications by our lab is inserting Smac
gene in the genome of VSV to generate armed VSV-S and VSV-Δ55S. The hypothesis is based
on the fact that VSV infection triggers apoptosis through the intrinsic mitochondrial pathway, so
overexpression of Smac via infection by armed VSV will reinforce apoptosis and increase the rate

of cell killing. We conducted several experiments to examine effects of the inserted gene in viral
replication and the enhancement in killing cancer cells compared to wild type VSV.
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CHAPTER 1: INTRODUCTION

1.1

A brief overview on oncolytic viruses
Cancer is one of the deadly diseases around the world. It is the result of genetic or epigenetic

issues which make changes in normal cells, driving them to become cancerous cells. Malignant
cells differ from healthy cells in different aspects; they grow and divide non-stop, which eventually
leads to formation of a tumor; tumor cells do not connect to each other, undifferentiated, and have
much more variability in cell size and shape; they are able to evade immune system and etc.
There are several ways to treat cancers. The first approach being used more than 4,000
years ago is surgery. The next method was radiotherapy after discovery of X-rays, and another
common treatment is chemotherapy (1).
Each of these approaches has their side effects and in many cases patients suffer a lot of
pain without being cured. Because of these issues, scientists look for new approaches to overcome
these barriers. One of the promising approaches is the use of viruses. The term onco in Latin means
cancer and lytic refers to cell destruction or lysis. “Oncolytic viruses” are the ones which applied
to destroy cancer cells while having no effects on normal cells.
The discovery of tumor regression by using viruses was in 1912 by observing a patient
with cervical carcinoma, showing significant recovery after rabies vaccination for prophylactic
treatment after being bitten by a dog (2) . Other reports also showed Burkitt’s and Hodgkin’s
lymphomas treatment after infecting with measles virus (3). These phenomena brought much
attention to using viruses as an alternative technique instead of common methods for tumor
destruction. During 1950s and 1960s, many trials took place and several viruses were tested in
vivo and in humans. In one study a vaccine strain of rabies virus was applied in patients with
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melanomatosis and the results showed tumor regression for some of them. In the following
attempts, the oncolytic efficacy of adenovirus serotype type 4, flavivirus West Nile virus (strain
Egypt 101), the paramyxoviruses mumps and Newcastle disease virus (NDV) were tested. There
are reports showing use of different kinds of viruses in patients with cervical cancer and other
types of advanced cancers. In most cases tumor destruction was not in the way that scientists
expected and many side effects also were observed, which causes a halt in these studies (4), (5).
These failures continued about three decades, which may be because of lack of enough
knowledge about viral biology, cell cycle control and unsafety of viral treatment. In the late 1980s,
advancements in genetic engineering, gene therapy, viral biology, tumor immunology and
molecular genetics brought new attentions to oncolytic viruses and many achievements have been
made in this area (3).
One of the great advances in the field occurred in 1991, when Martuz et al. reported about
a genetically modified herpes simplex virus type I (HSV-1) with a mutation in the thymidine kinase
(TK) gene (6). This mutant virus was able to infect and replicate selectively in cancer cells and
was efficient in treating brain tumors. This advancement brought attention to improve oncolytic
effects of viruses by altering viral genome.
To date, adenoviruses, poxviruses, HSV-1, coxsackieviruses, poliovirus, measles virus,
Newcastle disease virus (NDV), reovirus, and others, have entered into early-phase clinical trials.
The first genetically modified oncolytic virus approved in China for head and neck cancer in
October 2005 was an E1B-deleted adenovirus named Oncorine (H101, the same construct as
ONYX-015) (6). The second one approved by the US Food and Drug Administration (FDA) in
2015 was a modified herpes simplex virus type 1 (HSV-1), encoding granulocyte–macrophage
colony-stimulating factor (GM-CSF). This virus was named T-Vec (talimogene laherparepvec,
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IMLYGIC, formerly OncoVEXGMCSF), and was used for patients with advanced melanoma (6),
(7), (8).
The oncolytic viruses have specific characteristics which make them very important in
treating malignant cells. First of all, they selectively target cancerous cells, either inherently or by
some genetically modifications such as insertion or deletion of genes in their genome or other
methods to make them more specific to target tumors. This feature improves the safety of applying
these viruses. The second feature is that they will not produce any resistance, since their
mechanism of actions includes several pathways for tumor destruction. Another advantage of these
viruses is amplification through the course of treatment because of its replication, which is opposed
to classical drugs that decrease with time in cancer treatment (9).
Oncolytic viruses can be divided in two major groups. The viruses which are inherently
able to infect tumor cells and destroy them without having pathogenic effects in humans. This
group includes autonomous parvoviruses, myxoma virus (MYXV; poxvirus), Newcastle disease
virus (NDV; paramyxovirus), reovirus, and Seneca valley virus (SVV; picornavirus). The second
major group includes genetically modified viruses which have undergone some changes to
improve their ability to target cancerous cells, including measles virus (MV; paramyxovirus),
poliovirus (PV; picornavirus), vaccinia virus (VV; poxvirus), adenovirus (Ad), herpes simplex
virus (HSV), VV, and vesicular stomatitis virus (VSV; rhabdovirus)(9).

1.2

Mechanism of action by oncolytic viruses
The pathways in which oncolytic viruses used to kill cancer cells can be categorized in two

major approaches (Fig.1). One will be killing tumor cells directly as the result of viral replication
by using cellular transcription and translation mechanisms of host cells (malignant cells). Direct
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lysis of infected cells which is the result of cell death happens through different mechanisms of
cell death, including apoptosis, autophagy and necrosis. The process of direct cell killing by
oncolytic viruses often depends on the type of virus, dosage, the efficiency of targeting a cell
receptor, replication of virus, response of cancer cells to viral infection, and the different forms of
cell death.
The termination of virus replication cycle results in cell lysis and release of viral particles,
tumor-associated antigens (TAAs), cellular damage-associated molecular patterns (DAMPs) like
calreticulin, heat shock proteins, high-mobility group protein B1 (HMGB1), pathogen-associated
molecular pattern (PAMPs) molecules, cytokines (for example, type I IFNs, tumour necrosis
factor-α (TNFα), IFNγ, and interleukin-12 (IL-12)) and cellular ATP in a highly inflammatory
process, termed “immunogenic cell death”.
The other major pathway is activation of the host immune system in response to viral and
tumor antigens. These antigens activate antigen-presenting cells (APCs) such as dendritic cells
that activate natural killer cells and promote activation of antigen-specific CD4+ and CD8+
cytotoxic T lymphocytes. These triggers of the immune system result in destruction of infected
and uninfected tumor cells (7), (8) , (9), (10), (11).
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Figure 1. Mechanism of actions by oncolytic viruses. Adapted from (11).

Some viruses are able to selectively infect cancer cells and replicate in them, while others
may enter both normal and tumor cells and their replication will be ended in normal cells through
antiviral machinery of the host cell. The signaling pathway to eliminate viral replication is complex
and may trigger through local interferon (IFN) release or through intracellular Toll-like receptors
(TLRs), which are activated by viral elements.
TLRs are receptors which will be activated by recognition of repeated sequences called
PAMPs, including viral particles like DNA, RNA and viral proteins. Activation of TLR signaling
will induce host immune responses, resulting in termination of viral replication. Another pathway
to eliminate virus is through IFN release and following activation of PKR (intracellular protein
kinase) which recognizes double-stranded RNA and other viral particles, resulting in termination
of cell protein synthesis and eventually cell death and removal of virus (7).
In cancer cells IFN signaling pathway and PKR may be abnormal and because of that, the
termination of virus replication will not take place as in normal cells. PKR may be active in some
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of cancer cells such as low-grade tumors, causing difficulties in activities of oncolytic viruses and
their efficiency (7).

1.3

Vesicular stomatitis virus, mechanism of replication
1.3.1

Classification of VSV

Vesicular stomatitis virus (VSV) is an enveloped virus with a negative sense,
nonsegmented, single strand RNA (nnsRNA) which belongs to Rhabdoviridae and is placed in the
order Mononegavirales. This virus can infect a wide range of mammals such as horses, cattle, pigs
and insects and it causes vesicular lesions in the tongue, oral tissues, udders, and hooves. Vesicular
stomatitis is a self-limiting disease and in most cases the infection is not fatal. Infection in humans
by VSV is asymptomatic and mild flu like symptoms has been reported after VSV infection. Only
accidental cases of human infections have been reported in animal-handlers and laboratory
researchers (12-14).
VSV has two different serotypes, Indiana (VSVI) and New Jersy (VSV NJ), which are
distinguished by neutralizing antibodies against the G protein. The other difference between these
two serotypes is the number and composition of amino acids which showed only 50% identity.
The viral proteins also differ in post translational modification and folding. Infection by New
Jersey strains is more severe and happens more often than Indiana strains. However, these two
stereotypes exhibit similar properties and many studies have been done on VSVI stereotype (13).
VSV has a simple viral genome which encodes five genes, it has a short replication cycle
and can infect almost all vertebrate cells and many invertebrate cells. Because of these properties
it has been a great model to study basic aspects of virus biology and viral pathogenesis in both in
vitro and in vivo systems (14).
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1.3.2

Structure of VSV

The mature form of VSV has a bullet shape, and the dimension is approximately 180 nm
in length and 80 nm in width. The virion is composed of the host derived plasma membrane, the
envelope, and an internal ribonucleoprotein core. The genomic RNA of VSV is very simple and
consists of 11, 161 nucleotides. During infection VSV synthesizes five sub-genomic mRNAs that
encode its five different proteins: nucleocapsid (N), phosphoprotein (P), matrix (M), surface
glycoprotein (G) and large polymerase subunit (L). The five genes and leader and trailer regulatory
sequences arranged in the order 3’-(leader), N, P, M, G, L, (trailer)-5’,(12, 15). The 47 nt leader
and the 59 nt trailer contain sequences functional for transcription, replication and virus assembly.
Each gene is flanked by sequences important for generation of capped and polyadenylated mRNAs
(Fig.2).
The negative sense, single stranded VSV RNA is enrapped by multiple copies of N protein,
forming a helical structure providing a nuclease resistant complex, and is encapsulated in a bullet
shaped viral particle (16).
The N protein consists of 422 amino acids, with a net positive charge and always is tightly
associated with viral genome inside the virion particle as well as in the infected cells. Crystal
structure of N protein bound to RNA revealed that the N protein consists of two separate lobes and
the RNA is sequestered inside the grove generated by these two lobes (17). The N protein plays
roles in the assembly and regulation of transcription and replication of the N-RNA template (18,
19). The N-RNA complex serves as a template for mRNA synthesis as well as genomic RNA
replication.
The N-RNA complex is associated with viral RNA-dependent RNA polymerase (RdRp)
which is a complex of the L protein (241 kDa) and the P protein (29 kDa), forming viral
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ribonucleoprotein (RNP) complex, responsible for viral transcription and genome replication (20,
21).
The P protein has 265 amino acids and forms a complex with the N protein known as NºP complex, before polymerization of N onto the RNA genome (22, 23). The complex is delivered
to the replication site by interaction of P with the L protein and the encapsidation happesn by
association of N and RNA genome. Since the L polymerase subunit cannot recognize
nucleocapsid, P binding is essential for RNA recognition by the L protein and viral replication and
transcription. The structure of VSV nucleocapsid in association with the P protein has been solved.
It was suggested that th eN protein and the P protein undergo conformational changes upon
interaction with the RNA to accommodate the L protein for transcription and replication (17).
The L protein with molecular weight of 250 kDa is essential for viral replication and
transcription and functions as a catalytic subunit of the viral polymerase. In addition to RNA
synthesis, the L protein also catalyzes mRNA cap addition and cap methylation (24).
VSV has two membrane proteins: the M protein is an internal peripheral membrane protein
that is associated with both the nucleocapsid and the lipid bilayer, and the G protein is an integral
transmembrane protein that is present on the surface of the virion.(25).
The M protein is one of the most abundant viral proteins and consists of 229 amino acids.
The N-terminal region constitutes the signal for membrane binding. The M protein is essential for
virus assembly by interacting with the nucleocapsid, the G protein and the cellular plasma
membrane, resulting in a bullet shaped structure of virion. The M protein is also important for
release of viral particles by budding from the host cells. The M protein plays a crucial role in virus
pathogenesis by inhibiting expression of antiviral gene products such as interferon, and proteins
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for mRNA export blockage from the nucleus to thwart host innate immune mechanisms. The M
protein can activate the intrinsic apoptotic pathway in mammalian cells (26-34).
The G protein is a type I transmembrane protein and is the only protein present in the virus
envelope. G proteins exist in the form of trimmers. It is responsible for attachment to the cellular
receptor and interactions with the M protein during virus budding. Low pH-dependent
conformational changes of the G protein to induce membrane fusion inside the endosome is
necessary to release the virion content. VSV particles lacking the G protein are unable to infect
cells (25, 34-37).

Figure 2. VSV virion structure and genome organization. VSV encodes five structural proteins:
nucleocapsid (N), phospho- (P), matrix (M), glyco- (G), and large (L) proteins. The VSV genome
is arranged in the order 3’-(leader), N, P, M, G, L, (trailer)-5’. Adapted from(20).
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1.3.3

VSV life cycle

VSV replicates entirely in the host cell’s cytoplasm. The replication of VSV is initiated
after attachment of the G protein to the cell receptor (Fig.3). The host receptor is the LDL receptor
and its family members (38, 39). Following attachment, VSV enters host cell through clathrin
mediated endocytosis and enters endocytic pathway (40, 41). The pH drops in the endosome (pH
below 6.5), leading to a conformational change of the G protein to mediate the fusion of endosomal
membrane with the viral membrane and eventually release of ribonucleoprotein (the RNP
complex) into cytoplasm where viral replication and transcription take place (42).
During primary transcription, RdRp recognizes specific signals in the N-RNA template
and initiates transcription of viral genes directly from the RNA viral genome. The polymerase
complex initiates binding at the 3’ end of the genome and transcribes 5 mRNAs that are capped
and methylated at the 5’end, and polyadenylated at the 3’end in a sequential manner. Each gene is
separated by an intergenic region containing signals for poly adenylation and transcriptional
start/stop sequences where polymerase complex stutters. There is a probability for RdRp
dissociation from the genome at these regions during the polyadenylation, before advancing to
transcription of the following gene. Since reinitiation does not always occur, there is a decreasing
level of the viral mRNAs (28, 43-45). The abundance of the genes near the 3’ end is higher
compared to the genes closer to the 5’end, so the N protein has the highest abundance followed by
graduate decreasing in the amounts of P, M, G and L mRNAs. Viral proteins will be produced by
translation of mRNAs by host ribosome and are required for viral genome replication.
During replication, the polymerase complex ignores all of the initiation, termination, and
polyadenylation signals utilized to produce mRNAs, and synthesizes a complementary full-length
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anti-genome. Replication of the genomes requires N and P proteins, and it has been proposed that
the P protein keeps the N protein in a soluble encapsidation competent form (22, 46).
The anti-genome will then act as a template and the polymerase complex will replicate the
full-length VSV genome. These newly synthesized genomes can be used as a template for
secondary transcription or assembled into new virions (33, 47).
M and G proteins play an essential role in the assembly and budding which take place at
the plasma membrane (48, 49). The G protein is glycosylated in the ER and transported to the
Golgi apparatus where the complete glycan moieties are added, and then through cellular secretory
pathway is transported to the plasma membrane, forming membrane microdomains which is
important for VSV budding (50). M proteins are also transferred to the plasma membrane where
they form microdomains in association with the plasma membrane independent of the G protein
(25, 51). In cytoplasm the viral genome is encapsidated by the N protein and assembled with the
polymerase complex (P and L proteins), then transported to the plasma membrane in a microtubule
dependent manner to become associated with M protein (52, 53). This complex is assembled into
mature VSV virions. The M protein recruits cellular proteins at the site of budding for final release
of mature infectious virions, (53-55).
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Figure 3. Schematic diagram of VSV life cycle. Steps of virus life cycle: attachment, endocytosis,
uncoating, genome replication, mRNA transcription, viral protein translation, viral assembly, and
budding are shown. Adapted from (15).

1.4

VSV as an oncolytic virus
VSV is a natural oncolytic virus which preferably targets and replicates in various types of

cancer cells, in vitro and in vivo (12, 56-58). Immune signaling pathways in malignant cells are
generally defective, which is important for proliferation and evasion from tumor suppression
mechanisms of host immunosurveillance (59, 60).
It has been shown that the effectiveness of VSV to replicate in immortalized and malignant
cells is mainly due to a defective of type I interferons (IFNs) pathway or PKR function (12, 61).
The interferons are a family of cytokines produced in response to viral infection and play essential
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roles in antiviral innate immunity response (32, 62). Defectiveness in PKR that mediates the innate
immune signaling pathway will cause the inability of cancer cells to suppress translation of viral
proteins (63, 64).
In addition, tumors with mutations in the tumor suppressor p53, or activated Myc- or Rassignaling cellular aberrations that occur in over 90% of all tumors, were reported to be susceptible
to VSV-mediated oncolysis (57, 65).
Replication of VSV in healthy cells with normal and effective antiviral immune response
will be suppressed because of both the innate and adaptive immune response (66, 67). In normal
cells, activation of the innate immune system following infection by VSV results in production of
beta interferon (IFN-β) which activates IFN stimulated genes to upregulate the antigen processing
machinery and activate antigen cells such as dendritic cells, NK cells and macrophages (68, 69).
Activation of the IFN signaling pathway results in viral gene expression suppression and infected
cell clearance via leukocytes (16, 69, 70).
Using VSV as an oncolytic vector has many advantages, making it a good platform for
onco virotherapy. First of all it has a short replication cycle which allows it to reach a high titer in
a short time of infection, resulting in faster spread of virus in the tumor and a fast lytic cycle (14).
Secondly, VSV will not cause any host-cell transformation nor any immune-mediated
pathogenesis. Thirdly, VSV has been studied for many years and its well-studied biology makes it
possible to manipulate the simple genome of VSV via reverse genetics to enhance its
oncoselectivity, safety, oncotoxicity and stimulation of tumour-specific immunity. Beside these,
the viral envelope glycoprotein (G) targets a large variety of cancer cells because of its ubiquitous
receptor mechanism, and the G protein has been modified to establish several pseudotype viruses
(71, 72). VSV is not a human pathogen likely because of the induction of strong immune responses
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to suppress viral replication and amplification so there is not any preexisting immunity in humans
that could limit clinical applications (73-75). VSV is not gene attenuated, which affects replication
and therefore oncolytic antitumor activity (76).

1.5

Modification of VSV
Many modifications have been made to VSV to generate recombinant VSVs (rVSV) to

improve tumor targeting, safety, oncotoxicity, reduction of premature immune clearance, inducing
controlled apoptosis and triggering anti-tumor immune response (14, 58). The improvements in
reverse genetic made it possible to manipulate the genome of VSV and generating novel VSV
vectors expressing genes of interest.
There are different approaches to enhance the oncolytic effects of VSV, including
combination of VSV with chemical agents, insertion of tumor suppressor genes in viral genome,
combining VSV with anti-angiogenic agents, radiovirotherapy, creating rVSVs expressing proapoptotic, immunomodulatory, or suicide cassettes, micro RNA targeting, stimulating interferon
induction, expression of cytokines or immune-stimulatory molecules (14, 77).
Some of recombinant VSVs which have been engineered for oncotherapy are summarized
in Table (1).
Table (1). List of potential recombinant vesicular stomatitis viruses created for oncotherapy
applications. Adapted from (14).
VSV modification

Virus description

VSV-IL4

rVSV expressing IL-4 cytokine with enhanced oncolytic activity

VSV-IFN

rVSV expressing IFN- gene, show oncolytic activity against metastatic
lung disease, and able to generate T cell response
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VSV-IL12

rVSV is expressing murine IL-12 gene show oncolytic activity against
squamous cell carcinoma.

rVSV- gG

rVSV expressing equine herpes virus-1 glycoprotein G, which acts as a
broad-spectrum viral chemokine binding protein

rVSV-UL141

rVSV expressing a protein from human cytomegalovirus which down
regulates the natural killer (NK) cell-activating ligand CD155 and inhibits
the function of NK cell

rVSV(MD51)-M3

rVSV expressing the murine gammaherpesvirus-68 chemokine-binding
protein M3 in modified matrix protein backbone with enhanced tumor
necrosis

DM51-VSV

DM51-VSV infection activated DCs to produce proinflammatory
cytokines (IL-12 and IFNs)

VSV-CD40L

rVSV expressing CD40L, a member of the TNF family expressed on the
surface of activated Th cells

VSV-p14

rVSV expressing p14 FAST protein increase oncolytic property

VSV-CD133

rVSV expressing CD133 (a marker for cancer stem cells) increase
specificity for CD133 expressing tumours.

VSV-IL15

rVSV expressing secreted version of human interleukin15, it enhances
both NK cell and T cell response

VSV-mp53

and VSV-mp53 and VSV-DM-mp53 both expressing high level of functional

VSV-DM-mp53

p53 in respective backbone VSV with chemical compounds

VSV-TK

rVSV expressing thymidine kinase of herpes virus, increase oncolytic
property

16

LCL161 and VSV- SMC and OV therapies combination also synergize in vivo by promoting
DM51

anticancer immunity through an increase in CD8+ T-cell response

TNF: tumor necrosis factor; DC: dendritic cells; NIS: sodium iodide symporter; SMC: Second
mitochondrial activator of caspase (Smac)-mimetic compounds.

1.6

Overall objective and experimental plan
The ultimate goal of oncolytic virotherapy is selectively killing cancerous cells. As

explained in previous section many modifications of VSV have been carried out to achieve this
goal. The aim of this study is to enhance oncolytic effects of VSV by engineering new armed VSV
via inserting Smac gene (full length or mature form) in the viral genome between the M and G
genes (Fig.4). The hypothesis is based on the fact that VSV infection induces apoptosis through
the intrinsic mitochondrial pathway (32, 78). Previous studies also showed that autophagy plays a
cytoprotective role and supports virus replication in VSV and some other virus infections, and
inhibition of autophagy will trigger apoptosis (79). Our optimal design will be induction of
apoptosis after having an adequate amount of virus production, which will be achieved by properly
expression of Smac with armed VSV-S (full length Smac inserted) and VSV- Δ55S (mature form
inserted).
Smac (Second mitochondria-derived activator of caspase), also known as DIABLO (Direct
Inhibitor of Apoptosis-Binding protein with LOw pI), is a mitochondrial protein. Upon presence
of apoptosis stimuli, the mature form of Smac, which is generated by cleavage of the mitochondrial
targeting signal from N-terminal domain of full length Smac, is released to the cytosol. Mature
form of Smac will interact with IAPs (inhibitor of apoptosis proteins) and prevent their association
with caspase 9 and therefore promote activation of caspase 3 and apoptosis (80, 81).
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We conducted several experiments to examine the effect of inserted Smac in viral
replication by using several cell lines and also evaluate the efficacy of armed VSV-S and VSVΔ55S in killing cancerous cells compared to wild type VSV.

Figure 4. Schematic diagram of inserted Smac in the viral genome of VSV.
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2

2.1

CHAPTER 2: EXPERIMENT

Cell lines and cell culture
HeLa, Vero, and T-47D cell lines were from ATCC (American Type Culture Collection,

Manassas, VA, USA). HeLa expressing GFPLC3 (HeLa GFP-LC3) cell line was a gift from Dr.
Wen-Xing Ding at the University of Kansas Medical Center, USA. Anal and oral carcinoma canine
tissues was kindly provided by Dr. Nicole Northrup, Associate Professor of Oncology at
University of Georgia (UGA).
HeLa, Vero and HeLa GFP-LC3 were cultured in Dulbecco’s Modified Eagle Medium
(DMEM, Gibco, Life Technologies Corporation, UK) supplemented with 10% fetal bovine serum
(FBS, American Type Culture Collection, Manassas, VA, USA) and 1% penicillin/streptomycin
(Gibco, Life Technologies Corporation, USA) at 37 °C, 5% CO2, in a humidified incubator. T47D cells were propagated in RPMI 1640 (American Type Culture Collection, Manassas, VA,
USA) supplemented with 10% FBS, 1% penicillin/streptomycin and human insulin at 37 °C, 5%
CO2, in a humidified incubator. Anal and oral carcinoma canine tissues were maintained in
DMEM containing 1% penicillin/streptomycin at 37 °C, 5% CO2, in a humidified incubator.

2.2

Viruses
Vesicular stomatitis virus expressing mCherry fluorescent protein (VSV-MCP), vesicular

stomatitis virus with full length Smac gene (Second mitochondrial-derived activator of caspase)
inserted between the M and G genes of VSV genome (VSV-S) and vesicular stomatitis virus with
the mature form of Smac (55 N-terminus amino acids removed) inserted (VSV-Δ55S) were from
Dr. Ming Luo.
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2.3

Plaque assay
The plaque assay, a well-known and accurate method for quantification of virion particles,

was used to measure the titer of viruses as plaque-forming units per ml (PFU/ml). The principle of
this assay is based on the infection of monolayer cells with different dilutions of the virus under
study (unknown concentration). Cells are washed with warm Dulbecco's phosphate-buffered saline
(DPBS) (Gibco, Life Technologies Corporation, USA) and the virus inoculum is added. After onehour virus absorption, infected cells are washed with DPBS again and are covered with an agarose
overlay to limit spread of the virus. The virus replicates within infected cells, which eventually
makes cells become lysed. The adjacent cells will become infected and after several infection
cycles, they will be lysed. The plaque refers to each group of lysed cells surrounded by uninfected
cells and is assumed as one original single virus. Staining monolayer cells with crystal violet makes
it easier to count plaques and by applying in the following formula, the titer of virus can be
measured.
𝑃𝐹𝑈/𝑚𝑙 =

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠
(𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) × (𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑣𝑖𝑟𝑢𝑠)

For this experiment, HeLa cells were grown in 12-well plates to the confluency around
90% and after washing with DPBS, serial dilutions of viruses (VSV-MCP, VSV-S and VSV-Δ55S)
were added to different wells. The plate was incubated at 37 ºC, 5% CO2, in a humidified incubator
for 1 h and meanwhile was rotated every 10 minutes. The cells were then washed with DPBS. For
overlay, 0.8% of agarose (SeaPlaque Agarose, Lonza) dissolved in DMEM without FBS was made
and about 700 µl was added to each well. The plate was placed in room temperature for about 10
minutes to let the overlay become solid. The plates were subsequently incubated for 24 to 48 h and
monitored routinely to check the plaque formation. For fixing the cells, formaldehyde (Formalin
solution, neutral buffered, 10%, Sigma) was added to each well and kept in room temperature for
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30 minutes. Before staining, formaldehyde and agarose overlay were rinsed off with water and
cells were covered with small amount of 0.1% crystal violet solution (Crystal Violet, 1% stain,
Fisher Science Education) and stained for 5 to 15 minutes. The crystal violet solution was washed
off gently with water and the plaques were counted for each virus.

2.4

Virus Propagation
HeLa or Vero cells were seeded on 150 mm plates using DMEM supplemented by 10%

FBS and 1% penicillin/streptomycin and incubated at 37°C, 5% CO2, in a humidified incubator
until reaching the confluency of 80-90%. After removing the media, cells were washed with DPBS
and the inoculum of VSV-MCP, VSV-S or VSV-Δ55S at MOI=0.1 was added. MOI refers to
multiplicity of infection, defined as
𝑃𝐹𝑈 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠

MOI= 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
The plates were incubated for one hour, meanwhile rotated every 10 minutes to allow virus
adsorption. After virus absorption, 12 ml of fresh DMEM without FBS was added to each plate,
and the plates were incubated for 48 h. Based on the rate of virus replication, the incubation time
may differ for each cell line or virus.

2.5

Virus purification
The supernatant from plates infected by different viruses was collected and centrifuged at

9,500 rpm for 15 minutes at 22 °C for clarification. The clarified virus-containing supernatants
were collected in new clean tubes and were centrifuged at 16,100 rpm for 2 hours, at 4 °C. The
pellets were resuspended in phosphate-buffered saline (PBS) (Gibco, Life Technologies
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Corporation, USA) with 5% sucrose, and the titers were determined by plaque assay. The purified
viruses were stored at -20 °C for further usage.

2.6

Infection of canine oral and anal carcinoma tissues
The tissues were deposited in DMEM supplemented by 10% FBS and 1%

penicillin/streptomycin. In the cell culture hood, using a sterilized biopsy core and forceps,
different cores from various regions of tissues were collected and each core was divided evenly in
two halves with a sterilized razor blade. In different wells in a 12-well plate, tissues were deposited
and washed three times by DPBS. 1×105 PFU of VSV-S and VSV-MCP were used to infect the
tissues, and at different time point of post infection (24, 48 and 72 h) the supernatant was collected
to determine the virus titer by plaque assay.

2.7

Western blot
HeLa cells were grown in 60 mm plates using DMEM supplemented with 10% FBS and

1% penicillin/streptomycin. For western blot, cells were washed with ice-cold PBS and were lysed
by adding 1 ml RIPA Lysis Buffer (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid,
10% NP-40, 10 mM EDTA, 10X, Millipore). By aid of a cell scrapper, adherent cells were
detached and cell suspensions were transferred to a new clean Eppendorf tube. The tubes were
centrifugated for 1 to 5 minutes at 13,000 rpm using a micro centrifuge, and supernatants from
each tube were transferred to new tubes. The lysates were mixed with the equal volume of Laemmli
buffer (4% sodium dodecyl sulfate (SDS), 10% 2-mercaptoethanol, 20% glycerol, 0.004%
bromophenol blue, 0.125 M Tris-HCl, the pH adjusted to 6.8), and then boiled for 5 minutes at
100 °C, followed by spin down for 1 minute.
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Samples and a protein ladder (GeneRuler, #SM1811/2) were loaded in a 15% SDS-PAGE
gel, and then the cassette holding the gel was placed in a tray containing the running buffer (25
mM Tris base, 190 mM glycine, 0.1% SDS, the pH adjusted to 8.3). The electrophoresis was
carried out at a constant 100 v for 1-2 hour.
After gel electrophoresis the proteins from the gel were transferred to the nitrocellulose
membrane using a Bio-Rad Mini Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell apparatus
(Mini Trans-Blot® Cell and Criterion™ Blotter). In the transfer process, voltage was applied to
transfer the proteins from the gel to the membrane. First, the membrane was cut to the dimension
of the gel and was soaked in transfer buffer (25 mM Tris Base Saline (TBS), 192 mM Glycine,
20% Methanol, pH: 8.3) to make it completely wet. The membrane was placed between the gel
and the positive electrode in a sandwich. The sandwich was setup by placing sponges at each end,
filter papers to protect the gel and blotting membrane, and the gel and the membrane. The sandwich
was held with a gel cassette holder and placed in the buffer tank that was filled with transfer buffer.
The negatively charged proteins were transferred to the membrane from the gel by applying
voltage that generated 120 milliampere for around 2 hours.
The next step was blocking the membrane with 2% BSA (bovine serum albumin) dissolved
in 1% TBST (Tris buffered saline-Tween 20) at 4°C for 2 hours for preventing antibodies from
binding to the membrane nonspecifically. The membrane was washed three times by TBST 1%
and incubated with the desired dilution of primary antibodies overnight at 4°C. The membranes
were washed three times with TBST 1%, 5 minutes for each wash and incubated with the
secondary antibody at room temperature for 1 hour. The washing step was repeated. For
visualizing the bands, the membrane was incubated with Horseradish peroxidase substrate
(Luminata Forte, Western HRP Substrate) in a dark place for 5 to 10 minutes. After removing the
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excess reagent, the membrane was covered in a transparent plastic bag and a film was put on top
inside a film cassette. The images were developed using a film developer machine (X-OMAT
2000A, Kodak). Protein molecular weights were estimated by comparing visible bands from each
sample to bands generated from the protein ladder.
Table (2). List of primary and secondary antibodies used for western blotting
Antibody

Dilution

Type

Company

β-actin

1:1000

Rabbit polyclonal

Abcam company (#ab8227)

GAPDH

1:1000

Rabbit polyclonal

Abcam company (#ab9485)

Smac

1:500 or

Rabbit Monoclonal

Epitomics (#1012-1)

Rabbit Ab

Cell Signaling Technology

1:1000
Cleaved Caspase-3

1:500 or
1:1000

Caspase-9

1:500 or

(#9661)
Rabbit Ab

1:1000
LC3 A/B

1:500 or

(#9502)
Rabbit Ab

1:1000
Secondary AntiRabbit

1:1000

Cell Signaling Technology

Cell Signaling Technology
(#4108)

Polyclonal, Goat anti-

Thermo Fisher Scientific (#

Rabbit IgG

31460)
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Secondary Anti-

1:10000

Mouse

Polyclonal, Goat anti-

Thermo Fisher Scientific (#

Mouse IgG

31430)

GAPDH and β-actin were used as a loading control and all antibodies were diluted in 2% BSA
dissolved in 1% TBST.
2.8

Cell Viability Assay
The MTT assay, a sensitive, quantitative and colorimetric experiment, was used to

determine cell viability. MTT, a yellow tetrazolium salt, stands for 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide. It may be reduced by viable cells containing NAD(P)Hdependent oxidoreductase enzymes to formazan, an insoluble crystalline product with a deep
purple color.
Formazan crystals are then dissolved using a solubilizing solution (stop solution) and absorbance
is measured at 500-600 nanometers using a plate-reader. The darker the solution, the greater the
number of viable, metabolically active cells will be.
For calculating the percentage of viable cells, the absorbance reading of the blank (or background,
the ones treated by 1% Triton) was subtracted from all samples. Absorbance readings from test
samples was divided by those of the control and multiplied by 100 to give the percentage of cell
viability.
% 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 =

𝑎𝑏𝑠 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑎𝑏𝑠 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
× 100
𝑎𝑏𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑎𝑏𝑠 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑

For this experiment, T-47D cells were seeded in 12-well plates, and maintained in RPMI 1640
supplemented with 10% FBS, human insulin and 1% penicillin/streptomycin. After reaching to
around 80% confluency, cells were washed with DPBS and infected with VSV-MCP, VSV-S and
VSV-Δ55S, respectively, at MOI=5. Supernatants were collected at 24 and 48 h to examine titer
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of viruses. The uninfected cells were used for control and background absorbance. For wells of
background absorbance, 1% Triton X-100 (dissolve in PBS) was added to kill cells. Cells viability
were measured after 24 and 48 h post infection. After removing the media, 200 µl of warm PBS
and 30 µl of MTT dye (CellTiter 96®, Promega Corporation, and USA) were added to each well.
Plates were incubated at 37 °C, in a humidified incubator for about 2 hours until the purple color
has appeared. The reaction was stopped by adding 200 µl of stop solution (Solubilization
solution/Stop Mix, Promega Corporation, USA) and plates were incubated at room temperature
while shaking for 5 hours. MTT dye is sensitive to light so that the steps after adding dye were
performed in a dark place and plates were covered. The final step was reading the absorbance at
570 nm using a plate reader and the percentage of cell viability was calculated according to the
given formula.

2.9

Autophagy assay
Microtubule-associated protein light chain 3 (LC3), involved in the formation of

autophagosomes and autolysosomes, is a marker to evaluate autophagy. One reliable and
quantitativ assay to evaluate autophagy is to monitor, characterize and measure the number of
GFP-LC3 puncta (Green fluorescent protein diffused at the amino terminus of LC3) by
fluorescence microscopy (82). For this method, HeLa cell line expressing GFP-LC3 was grown in
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Coverslips were sterilized,
following protocol for Glass Coverslip Cleaning (Light microscopy core facility, Duke
University). Base on the protocol, glass coverslips were cleaned by using HCl (1M) at 50-60 ºC
and occasional agitation for 4 to 16 hours. They were then washed with distilled water to remove
acid, followed by rinsing with ethanol (100%). After washing, the coverslips were dried using

26

paper tissues and kept in a clean container under laminar hood. For cell culture, sterilized
coverslips were placed at the bottom of each well in 6-well plates and 1 ml of cell suspension was
dispensed in each well.
The plates were checked routinely to make sure that cells were attached to coverslips and were
growing well. Before imaging, old medium was aspirated, and cells were washed with PBS and
fixed with 1 ml formaldehyde (Formalin solution, neutral buffered, 10%, Sigma) for 15 min at 37
°C in a humidified incubator. Afterwards, formaldehyde was aspirated and coverslips were rinsed
with PBS, and the remaining PBS was gently removed by putting them on the tissue. The final
step was adding one drop of slide oil on a glass slide and the coverslip was mounted on the slide,
in the orientation that the cells on the coverslip faced the oil. Slides were labeled properly and
observed under a fluorescent microscope. A number of images was taken from each coverslip and
the average number of GFP-LC3 puncta was determined from a number of cells.
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3

3.1

CHAPTER 3: RESULTS

Comparison of virus growth curves
VSV is a good platform as an oncolytic virus and many modifications have been done to

enhance its tumor targeting, safety and oncotoxicity in order to overcome premature immune
clearance and/or to induce or stimulate anti-tumor immune responses (58). VSV is a potent inducer
of cell death due to the activation of multiple apoptotic pathways (78, 83-86). Some studies also
showed that overexpression of Smac/DIABLO sensitized tumors to chemotherapeutic drugs, or
combination of oncolytic viruses with Smac could eradicate tumors (80, 81, 87, 88). Based on all
previous studies, we hypothesized that modification of VSV genome by inserting Smac gene (full
length and mature form) as an expression unit between M and G genes will promote more robust
oncolysis by this armed VSV. The first thing to examine about armed VSV-S was to evaluate the
impact of inserted Smac gene on viral replication. For this study virus growth curves were
determined to evaluate replication of armed viruses compared to VSV-MCP as a control.
Study of virus growth curves was carried out by using HeLa cells as described below.
HeLa cells was grown to the confluency of 3.2 x 106 cells per 60 mm plate and were
infected with VSV-MCP and VSV-S, respectively, at different MOIs (MOI= 1, 0.1, 0.01). The
volume of viruses needed for each MOI was calculated and fresh DMEM without FBS was added
to the final volume of 1 ml. The plates were kept at 37 °C, 5% CO2, in a humidified incubator for
one hour and meanwhile were rotated every 10 minutes to allow virus adsorption and penetration
evenly in the plates. After that, the plates were washed with DPBS and 3 m of DMEM without
FBS added to each plate and were kept in the incubator. Samples from supernatant were taken at
different time points (4, 8, 12, 24 and 36 h of post infection). The aliquots were stored at -20°C
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until all samples were collected and their titers were determined by plaque assays in triplicate.
Virus growth curves were plotted based on the average of virus titers at different MOI versus time
point post infection. Our results (Table (3), Fig. 5) indicate that VSV-S grew at the same or higher
rate as VSV-MCP, suggesting that insertion and expression of Smac does not comprise VSV
replication.
Table (3). Titer of VSV-MCP and VSV-S at different MOI (HeLa cells)
MOI=1

POST
Virus

VSV-S

MOI=0.1

MOI=0.01

INFECTION

# of

PFU/ml

# of

PFU/ml

# of

PFU/ml

(h)

plaques

(log 10)

plaques

(log 10)

plaques

(log 10)

6

7.48

12

7.78

18

7.95

9

7.65

9

7.65

19

7.97

7

7.54

8

7.6

11

7.74

36 h (10-6)

STDEV

0.08621678

0.092916

0.12741

Average

7.55

7.67

7.88

1

6.69

5

7.4

11

7.74

3

7.18

7

7.54

8

7.6

9

7.65

8

7.6

10

7.7

VSV36 h (10-6)
MCP

STDEV

0.48003472

0.102632

0.072111

Average

7.17

7.51

7.68

24 h (10-5)

13

6.81

54

7.43

51

7.41

19

6.97

43

7.33

32

7.2

33

7.21

65

7.51

38

7.28

STDEV

0.20132892

0.090185

0.105987

Average

6.99

7.42

7.29
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MOI=1

POST
Virus

MOI=0.1

MOI=0.01

INFECTION

# of

PFU/ml

# of

PFU/ml

# of

PFU/ml

(h)

plaques

(log 10)

plaques

(log 10)

plaques

(log 10)

42

6.32

92

6.66

83

6.62

46

6.36

81

6.61

62

6.49

47

6.37

67

6.52

65

6.51

VSV24 h (10-4)
MCP

VSV-S

STDEV

0.02645751

0.070946

0.07

Average

6.35

6.59

6.54

12 h (10-4)

56

6.44

36

6.25

7 (10-4)

5.54

47

6.37

39

6.29

5 (10-4)

5.39

46

6.63

25

6.09

42 (10-3)

5.32

STDEV

0.13453624

0.10583

0.112398

Average

6.48

6.21

5.41

65

5.51

14

4.84

27 (10-2)

4.13

67

5.52

11

4.74

22 (10-2)

4.04

61

5.48

9

4.65

15 (10-2)

3.87

VSV12 h (10-3)
MCP

STDEV

0.02081666

0.095044

0.132035

Average

5.5

4.74

4.01

8h
VSV-S

18 (10-4)

5.95

13 (10-3)

4.81

14 (10-2)

3.84

23 (10-4)

6.06

14 (10-3)

4.84

25 (10-2)

4.09

27 (10-4)

6.13

16 (10-3)

4.9

31 (10-2)

4.19

STDEV

0.09073772

0.045826

0.180278

Average

6.04

4.85

4.04

30
MOI=1

POST
Virus

MOI=0.1

MOI=0.01

INFECTION

# of

PFU/ml

# of

PFU/ml

# of

PFU/ml

(h)

plaques

(log 10)

plaques

(log 10)

plaques

(log 10)

45 (10-2)

4.35

27 (10-1)

3.13

6 (10-1)

2.47

52 (10-2)

4.41

30 (10-1)

3.17

8 (10-1)

2.6

47 (10-2)

4.37

39 (10-1)

3.29

10 (10-1)

2.69

8h
VSVMCP
STDEV

0.0305505

0.083267

0.110604

Average

4.37

3.19

2.58

4h
VSV-S

41

3.31

0

0

0

0

43

3.33

0

0

0

0

38

3.28

0

0

0

0

STDEV

0.02516611

Average

3.3

4h

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

VSVMCP
Average
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Viruses Growth Curves
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Figure 5. Growth curves of VSV-MCP and VSV-S. Supernatants from infected HeLa cells
(MOI=0.01, 0.1, 1) were collected at 4, 8, 12, 24 and 36 h post infection and titers were measured
by plaque assay.

3.2

Virus purification
For studies of antitumor activities in animal models, viruses were purified and

concentrated. Supernatants from infected HeLa cells (MOI=0.1) were collected and viruses were
purified following steps of the purification protocol described at section 2.5. The titers of the
purified VSV-S and VSV-MCP were examined by plaque assay (Fig. 6. and Table (4)). The results
showed VSV-S grew at the same and/or higher titer as VSV-MCP.
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Viruses were also propagated in Vero cells. Supernatants of infected Vero cells (MOI=0.1)
were collected and viruses were purified following steps of the purification protocol described at
section 2.5. The titers were determined by plaque assay. The similar pattern of growth was
observed for VSV-S and VSV-MCP infection of HeLa cells (Fig. 7).
All of these data indicating that armed VSV has the similar or higher titer compare to VSVMCP and we conclude that insertion and expression of Smac does not comprise VSV replication.

Table (4). Titer of purified VSV-MCP and VSV-S, using HeLa cells
Log10PFU

Virus
VSV-MCP

6.87

7.65

7.74

8.95

7.93

7.97

8.54

VSV-S

8.6

8.39

8.47

9.04

7.87

8.38

8.65
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Titer of Purified Viruses, using HeLa cells
9

Virus Titer, Log10PFU

8
7
6
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4
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2
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4

5
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Figure 6. Titers of purified VSV-S and VSV-MCP. Different purified samples were from
infected HeLa cells (MOI=0.1) and titers were measured by plaque assay.

Virus Titer, Log10PFU

Titer of Purified Viruses, using Vero cells
8
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4
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2
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0
1

2
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4

Prep Number

Figure 7. Titers of purified VSV-MCP and VSV-S. Different purified samples were from
infected Vero cells (MOI=0.1) and titers were measured by plaque assay.
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3.3

VSV-S enhanced apoptosis
Evidence from different literature showed that apoptosis pathway was triggered after VSV

infection through intrinsic or mitochondrial pathway (78, 84, 85). Several studies also confirmed
that overexpression of Smac or applying Smac mimetic compounds could directly trigger cancer
cell death or sensitized tumor cells to other cancer therapeutic agents (80, 81, 87, 89, 90). We
wanted to investigate the enhancement of apoptosis through overexpression of Smac upon
infection by VSV-S, compared to VSV-MCP as a control. In order to evaluate apoptosis,
expression level of Smac, cleaved caspase 3 and 9 (key proteins involved in intrinsic apoptosis
pathway) were analyzed in HeLa cells following infection by VSV-S and VSV-MCP via western
blot. HeLa cells were grown in DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin and seeded in 100 mm plates. After removing the old media, cells were
washed with warm DPBS and infected with VSV-S and VSV-MCP, respectively. At different time
points (0, 12 and 24 h post infection), cells were washed by ice-cold PBS and lysed by RIPA lysis
buffer. Following steps described at section 2.7 and using Smac, cleaved caspase 3 and 9
antibodies, the level of these proteins was monitored (Fig. 8 and 9). The antibody used for detecting
Smac could detect full length (27 kDa) and mature form (21 kDa) of Smac.
The data in Fig. 8 showed a significant increase in the level of Smac expression following
infection of VSV-S. Since Smac (full length) was expressed by VSV-S during virus infection, this
increasing level was expected. Full length Smac expressed by VSV-S was processed to form the
mature Smac (Δ55 Smac). There was an increase in the level of mature Smac, but the majority of
Smac protein expressed by VSV-S was full length, which means Smac expression by VSV-S did
not result in premature release of Δ55 Smac so the virus could continue to be produced before
activation of apoptosis in the infected cell. At 24 h post infection, although the large portion of
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cells had died as indicated by the reduced level of GAPDH, the level of Smac expression was still
high. On the other hand, the level of mature Smac was reduced at 12 h post infection and its level
became hard to detect at 24 h post infection, upon infection of VSV-MCP. The rate of cell death
was also lower for cells infected by VSV-MCP compared to VSV-S, as indicated by the level of
GAPDH. One way for VSV to deplete mature Smac is by inducing mitophagy because mature
Smac resides in the intermembrane space of mitochondria. Another potential mechanism of Smac
removal is by Smac ubiquitination activated by wt VSV infection (91).
The results in Fig. 9 showed an increase in the level of cleaved caspase 3 after 24 hour post
infection by VSV-S. For VSV-MCP the bands were almost undetectable, which is consistence
with previous result confirming that intrinsic apoptosis pathway was not activated by VSV-MCP.
Unfortunately, we could not detect the level of cleaved caspase 9 to better evaluate apoptosis by
this experiment.

VSV-S

VSV-MCP

Smac-FL
Smac (mature)

GAPDH
0

12

24

0

12

24 h

Time post infection

Figure 8. Level of Smac (full length and mature) in response to VSV-MCP and VSV-S
infection. HeLa cells were infected by viruses and lysed at 0, 12 and 24 hour post
infection and subjected to western blot analysis. GAPDH was used as a loading control.
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VSV-MCP

VSV-S
Caspase 9

Caspase 3
Cleaved Cas-3
GAPDH

0

12

24

0

12

24 h

Time post infection

Figure 9. Evaluating levels of caspase 3 and 9 by western blot. HeLa cells were infected by
VSV-S and VSV-MCP. GAPDH was used as a loading control.

3.4

Assessing autophagy progression
Many studies showed that some viruses (such as NDV, VSV) take advantage of autophagy

to enhance viral replication and release (79, 92-97). It has been shown that NDV, which is in the
same virus class as VSV, induces autophagy. The level of LC3 II was increased in A549 cells
following infection by NDV (79). Based on these studies, autophagy appears to play a
cytoprotective role against apoptosis in infected cells.
Here we studied autophagy activation after VSV-MCP and VSV-S infection, by using
HeLa cell lines expressing GFP-LC3 (98) through monitoring GFP-LC3 puncta.
HeLa cells expressing GFP-LC3 were cultured in DMEM supplemented with 10% FBS
and 1% penicillin/streptomycin and seeded in 6-well plates with glass coverslip at the bottom. As
a positive control, rapamycin (2 µM), a well-known autophagy inducer by suppressing mTOR,
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was used. Chloroquine (40 µM), an inhibitor of autophagic degradation in the lysosomes, was
added to all media. 40 μM is the minimal saturating concentration of chloroquine necessary to
reach maximal suppression of autophagy in HeLa cells (98). After removing old media, cells were
washed with warm DPBS, and infected with VSV-S and VSV-MCP, respectively, at MOI=10.
The cells that were not infected and treated with rapamycin, considered as a positive control. At
different time points (0, 2, 6, 10 and 24 h post infection), coverslips were washed with DPBS, and
cells were fixed by formaldehyde (10%) for 15 min. Following steps as described in section 2.9,
slides were prepared and images were taken under a fluorescent microscope. The number of GFPLC3 puncta was counted for 15 cells under each different condition (Fig. 10).
The result showed VSV-MCP induced autophagy during infection, which was monitored
by appearance of GFP-LC3 puncta after 6 h post infection. After 10 h, there were few cells left on
coverslips and they had the same morphology as the control cells, which indicated that they were
not actually infected. For cells infected with VSV-S, the remaining cells on the coverslips were
much fewer. These results suggest that autophagy may promote viral replication and mainly plays
a cytoprotective role in infected cells.
To further confirm the role of autophagy in VSV infection, the conversion of LC3‑I to
LC3‑II was analyzed by western blot. In order to assess the level of LC3‑I and LC3‑II , HeLa cells
were were seeded into 6-well plates and infected with VSV-MCP and VSV-S, respectively, at
MOI=1.0 for 0, 12 and 24 hours. The expression level of LC3‑I and LC3‑II was analyzed via
western blot analysis described in section 2.7 , using LC3 antibody that was able to recognize LC3I at molecular weight around 16 kDa and LC3-II at 18 kDa, respectively, (Fig. 11). The results
showed after 24 h post infection, LC3-II was depleted for both VSV-MCP and VSV-S and the
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ratio of LC3-II/LC3-I did not seem to change much. However, this experiment needs to be repeated
because the cells may not be in a very healthy state before starting the experiments.

Number of Puncta per Cell
35

A

B

Number of Puncta

30
25
20
15
10
5
0

C

D

Figure 10. Puncta of LC3. (A) HeLa GFP-LC3 as a control, (B) rapamycin (2 µM) as a positive
control, after 10 h, (C) after 6 h of VSV-MCP infection and (D) after 6 h of VSV-S infection.
Chloroquine (40 µM) was added to media. (E) Number of GFP-LC3 puncta per cell. 15 cells were
counted under each condition.
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Figure 11. Levels of LC3 I and LC3 II. HeLa cells were infected by VSV-MCP and VSV-S,
respectively. Lysates were collected at 0, 12 and 24 h post infection and were analyzed by
western blot with LC3 antibody.

3.5

In vitro efficacy of cancer cell killing by VSV-MCP, VSV-S and VSV-Δ55S
In order to evaluate the potential of cancer cell killing, T-47D breast cancer cells were

seeded in 12-well plates and infected with VSV-MCP, VSV-S and VSV-Δ55S, respectively, at
MOI=5. Cell viability was measured at 24 and 48 h post infection by MTT assay. The results (Fig.
12, Tables (5) and (6)) showed, after 24 and 48 h post infection, although all cells were infected
by VSV-MCP but it could not effectively kill T-47D cells that have a high level of XIAP
expression (99). After 24 h post infection, VSV-S and VSV- Δ55S were able to kill 30% and 35%
of cells, respectively. The rate of cell death was also increased after 48 h post infection by armed
viruses. VSV-S killed more than 75% of T-47D cells and VSV- Δ55S was able to kill 82% of T47D cells.
We also measured the titer of collected supernatants at 24 and 48 h post infection by plaque assay.
Fig. 13 and Table (7) represented the titer of armed viruses (VSV-S and VSV-Δ55S) compared to
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VSV-MCP, which was consistence with results using HeLa cells. Interestingly at 24 h post
infection, the titer of VSV-Δ55S was near 2 log higher, compared to VSV-S and VSV-MCP, but
these differences reduced at 48 post infection, in the way that titer of VSV-S and VSV-Δ55S were
closer but still one log higher than VSV-MCP. This may suggest that VSV-Δ55S induced apoptotic
cell death sooner because no activation of Smac was needed, leading to a rapid spread of virus.

Table (5). Percentage of T-47D cell viability infected by VSV-MCP, VSV-S and VSV-Δ55S, at
MOI=5, after 24 h post infection
Sample

Control

VSV-MCP VSV-S

VSV-Δ55S

Triton 1%

1.492

1.629

1.225

1.134

0.337

1.715

1.668

1.124

1.248

0.287

-----

------

1.351

1.075

------

100%

100%

71%

65%

-------

Absorbance

% cell viability

41

Table (6). Percentage of T-47D cell viability infected by VSV-S and VSV-Δ55S, at MOI=5, after
48 h post infection

Sample

Absorbance

% cell viability

Control

VSV-S

VSV-Δ55S Triton 1%

1.306

0.390

0.410

0.153

1.783

0.665

0.503

0.223

1.468

0.565

0.491

0.246

100%

25.36%

19.88%

--------

T-47D cells viality (MOI=5, 24h)

T-47D cells viality (MOI=5, 48h)

120%

120%

100%

100%

80%

control

80%

60%

VSV-MCP

60%

40%

VSV-S

40%

20%

VSV-Δ55S

20%

0%

A

control
VSV-S
VSV-Δ55S

0%

24 h

B

48 h

Figure 12. In vitro efficacy of VSV-S and VSV-Δ55S. (A) After 24 post infection, VSV-MCP
could not kill T-47D cells effectively, but more than 35% of cells were dead by infection of armed
viruses. (B) The rate of cell death increased significantly at 48 h post infection by VSV-S and
VSV-Δ55S.

42

Table (7). Titer of armed viruses and VSV-MCP (MOI=5) at 24 and 48 h post infection, using T47D cells.
Viruses

VSV-MCP

VSV-S

VSV-Δ55S

Time point

24h

48h

24h

48h

24h

48h

Titer of

5.3

5.54

5.3

7

7.17

7.87

5.17

6.69

5.47

7.3

7.4

7.54

-------

-------

5.6

7.17

7.49

7.9

Average

5.235

6.115

5.456667

7.156667

7.353333

7.77

STDEV

0.091924

0.813173

0.150444

0.150444

0.165025

0.19975

virus
(Log10PFU)

Virus titers of T-47D infection
9

Virus Titer, Log10PFU

8
7
6
5

VSV-MCP

4

VSV-S

3

VSV-Δ55S

2
1
0

24 h

48 h

Figure 13. Virus titers from T-47D cells infected by different viruses (MOI=5).
Supernatants of infected T-47D cells were collected at 24 and 48 h post infection and titers were
measured by plaque assay.
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3.6

ex vivo infection of carcinoma canine oral and anal carcinoma tissues
We also confirmed the ability of VSV-MCP and VSV-S in ex vivo infection of carcinoma

canine oral and carcinoma anal tissues. Even cuts from different regions of the tissues were placed
in 12-well plate and washed three times with warm DPBS. 1×10 5 PFU of viruses was added to
each well and after one hour of virus absorption, the virus inoculum was removed and fresh media
were added. Supernatants of infected tissues were collected at 72 h post infection and titers were
measured by plaque assay. The titer of viruses confirmed the ability of viruses to infect and
replicate in canine carcinoma tissues (Fig. 14).

Oral Carcinoma

7

7

6

6

5
4
3
2
1
0

Virus Titer, Log10PFU

Virus Titer, Log10PFU

Anal Carcinoma

5
4
3
2
1
0

Figure. 14. ex vivo infection of canine carcinoma tissues with VSV-S and VSV-MCP, respectively.
Supernatants from canine anal and oral carcinoma tissues infected with VSV-S and VSV-MCP,
respectively, were collected at 72 h post infection and titers were measured by plaque assay.
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CHAPTER 4: CONCLUSIONS
Oncolytic virotherapy has caught a lot of many attention and is becoming one of the
promising methods to treat cancer (100). Applying virus will cause a direct oncolytic effect on the
tumor because of its replication and also will trigger the host immune response to viral particles,
tumor associated antigens and other proteins. The viruses need to have specific characteristics in
order to be appropriate for virotherapy. The safety aspect of administrating viruses must be
considered carefully, in the other words; they should be able to target cancerous cells and having
no harmful effects on healthy tissues. Advancement in genetic engineering made it possible for
researchers to design recombinant viruses, which were more specific, and having better oncolytic
effects (101, 102).
VSV has many prerequisites of a better oncolytic vector and different kinds of modification
have been done on its genome to enhance the efficacy of VSV to destroy malignant cells (12).
Previous studies showed that some viruses like VSV, NDV and many other viruses manipulate the
autophagy pathway to enhance their replication and survival. However, the exact mechanism on
how viruses take advantages of autophagy for their replication is still unclear in most cases and it
depends on cell types, virus strains or serotypes (12, 18). It also has been shown that, VSV
infection induces apoptosis through the intrinsic mitochondrial pathway (78, 84, 103) and
inhibition of autophagy enhances induction of apoptosis by VSV (95). Autophagy promotes viral
replication and plays a cytoprotective role in cancer cells by inhibiting apoptosis, so it should be
blocked by administrating autophagy inhibitor at later stage in order to trigger apoptosis and
having more profound oncolytic effects (79). Therefore, for having the best oncolytic effect, it is
necessary to inhibit autophagy after sufficient virus replication. We have designed two engineered
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viruses by inserting a suicide gene (Smac) in its full length (VSV-S) and mature form (VSV-Δ55S)
between the M and G genes of VSV genome to achieve this goal.
During induction of intrinsic apoptosis pathway, the mature form of Smac, originated by
the cleavage of 55 N-terminus amino acids that serve as mitochondrial targeting signal (MTS), is
released to cytosol. The mature form of Smac interacts with IAPs (inhibitory proteins of apoptosis)
in the cytosol, which results in the activation of caspases and apoptosis. The four hydrophobic
amino acids, Ala-Val-Pro-Ile, at the N-terminus of Smac are responsible for interacting with the
BIR2 and BIR3 domains of XIAP, resulting in the release of caspase-3 and caspase 9, respectively
(80, 81). Several studies showed that overexpression of Smac sensitized tumor cells to apoptotic
death. Therefore, engineering VSV by insertion of Smac should result in more apoptotic activities
of this virus.
Here we performed several experiments to evaluate and compare the oncolytic effects of
wild type VSV expressing mCherry fused P protein (VSV-MCP) as a control and armed VSV-S
and VSV-Δ55S.
The first thing to examine was the effect of Smac insertion on virus replication. Since VSV
genome is a negative sense single RNA strand, it serves as a template to synthesize five messenger
RNAs in a decreasing order of molar ratios as N>P>M>G>L which are then translated by host
ribosomes to produce viral proteins. The abundance of these proteins is related to location of
coding region from the 3′ end of the genome (104, 105). N, P and M proteins are essential for viral
assembly and replication, and therefore insertion of Smac between M and G genes should not have
any impact on armed VSV replication. Beside this, the level of Smac is also related to replication
of the armed VSV, which will not limit the replication cycle due to the delay of expression (based
on the obligatorily sequential of transcription of VSV genome).
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Based on the results of virus growth curve at different MOI, and titers of viruses using
several cell lines, the growth rate of engineered VSV was the same or higher compared to VSVMCP as a control, confirming that insertion of Smac does not comprise virus replication.
Our results also indicate that the rate of cell death increased upon infection by VSV-S or
VSV-Δ55S compare to VSV-MCP as a control. At 24 h post-infection VSV-MCP was not able to
effectively kill T-47D cells which have a high level of XIAP expression, but the percentage of cell
death were more than 35% by infection of VSV-S or VSV-Δ55S. The results also showed a
significant increase in cell death after 48 h post infection by armed viruses, which suggests that
these newly engineered viruses have a higher efficacy in killing cancerous cells compared to wild
type VSV.
We also investigated autophagy progression, by monitoring GFP-LC3 puncta at different
time points if infection by VSV-MCP or VSV-S using HeLa cells expressing GFP-LC3 .
Rapamycin (2 μM) was used as a positive control. The results showed appearance of puncta after
6 h post infection, indicating autophagy induction by VSV-MCP. After 10 and 24 h, few cells were
left having the same morphology as the control cells, suggesting they were not infected. For VSVS the rate of cell death was higher and it was difficult to find cells that were still present on the
coverslip. These data confirmed that autophagy induction by VSV mainly plays a cytoprotective
role and there was suppression of autophagy by VSV-S. However, more studies should be done in
order to evaluate autophagy progression by monitoring autophagy flux and the exact mechanism
on how VSV induces autophagy and inhibits apoptosis.
Another piece of evidence confirming induction of apoptosis following VSV-S infection
was assessing levels of Smac, cleaved caspase-3 and 9, which are the key proteins in regulating
apoptosis pathway. Western blot analysis of lysed HeLa cells infected by VSV-S and VSV-MCP,
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respectively, at 0, 12 and 24 h post infection, showed an increase in the level of Smac (mature
form) in VSV-S infected cells, indicating apoptosis induction and higher rate of cell death by VSVS comparde to VSV-MCP. There was also an increase in the level of cleaved caspase 3 after 24 h
post infection by VSV-S. Unfortunately we couldn’t detect the level of cleaved caspase 9 for this
experiment.
In conclusion, our results showed armed VSV by inserting Smac expressing unit in VSV
genome does not comprise viral replication and this enhanced the efficacy of armed viruses in
killing cancerous cells. Further investigation should be carried out to demonstrate how VSV
induced autophagy to inhibit apoptosis and to determine the mechanism of apoptosis induction by
VSV-S.
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